Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: Inhibitory effects of thiazolidinedione

Biochemical and Biophysical Research Communications

Volumn 317, Issue 1, 2004, Pages 24-29

  Onozaki, Akira ^a   Midorikawa, Sanae ^a   Sanada, Hironobu ^a   Hayashi, Yoshimitsu ^a   Baba, Tsuneharu ^a   Katoh, Tetsuo ^a   Watanabe, Tsuyoshi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Pioglitazone; PPAR ; Protein kinase C

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTAGLANDIN INHIBITOR; PROTEIN KINASE C INHIBITOR; THYMIDINE; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETOGENESIS; GLOMERULUS; MALE; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT;

ALKALOIDS; ANIMALS; BENZOPHENANTHRIDINES; CELL DIVISION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; GENE EXPRESSION; GLOMERULAR MESANGIUM; GLUCOSE; MALE; PHENANTHRIDINES; PROSTAGLANDIN D2; PROTEIN KINASE INHIBITORS; RATS; RATS, INBRED OLETF; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; THIAZOLIDINEDIONES; THYMIDINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1642463524     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.02.175     Document Type: Article

References (30)

1. Feldt-Rasmussen B., Mathiesen E.R., Jensen T., Lauritzen T., Deckert T. Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia. 34:1991;164-170.
2. Mogensen C.E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br. Med. J. 285:1982;685-688.
3. Zatz R., Dunn B.R., Meyer T.W., Anderson S., Rennke H.G., Brenner B.M. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 77:1986;1925-1930.
4. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., Horikoshi H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 37:1988;1549-1558.
5. Nakamura T., Ushiyama C., Suzuki S., Shimada N., Sekizuka K., Ebihara L., Koide H. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabetic Med. 18:2001;308-313.
6. Imano E., Kanda T., Nakatani Y., Nishida T., Arai K., Motomura M., Kajimoto Y., Yamasaki Y., Hori M. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care. 21:1998;2135-2139.
7. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1989;1309-1312.
8. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:1983;983-985.
9. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Nguyen H.V., Aiello L.M., Ferrara N., King G.L. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1994;1480-1487.
10. Hovind P., Tarnow L., Oestergaard P.B., Parving H.H. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney. Int. 57(Suppl. 75):2000;S56-S61.
11. de Vriese A.S., Tilton R.G., Elger M., Stephan C.C., Kriz W., Lameire N.H. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J. Am. Soc. Nephrol. 12:2001;993-1000.
12. Kim N.H., Jung H.H., Cha D.R., Choi D.S. Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. J. Endocrinol. 165:2000;617-624.
13. Rocco M.V., Neilson E.G., Hoyer J.R., Ziyadeh F.N. Attenuated expression of epithelial cell adhesion molecules in murine polycystic kidney disease. Am. J. Physiol. 262:1992;F679-F686.
14. Nakamura T., Tomita Y., Ichihara A. Density-dependent growth control of adult rat hepatocytes in primary culture. J. Biochem. (Tokyo). 94:1983;1029-1035.
15. Jakeman L.B., Winer J., Bennett G.L., Altar C.A., Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J. Clin. Invest. 89:1992;244-253.
16. Cooper M.E., Vranes D., Youssef S., Stacker S.A., Cox A.J., Rizkalla B., Casley D.J., Bach L.A., Kelly D.J., Gilbert R.E. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 48:1999;2229-2239.
17. Simon M., Grone H.J., Johren O., Kullmer J., Plate K.H., Risau W., Fuchs E. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am. J. Physiol. 268:1995;F240-F250.
18. Thomas S., Vanuystel J., Gruden G., Rodriguez V., Burt D., Gnudi L., Hartley B., Viberti G. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J. Am. Soc. Nephrol. 11:2000;1236-1243.
19. Nahman N.S. Jr., Leonhart K.L., Cosio F.G., Hebert C.L. Effects of high glucose on cellular proliferation and fibronectin production by cultured human mesangial cells. Kidney Int. 41:1992;396-402.
20. Sone H., Kawakami Y., Okuda Y., Kondo S., Hanatani M., Suzuki H., Yamashita K. Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells. Biochem. Biophys. Res. Commun. 221:1996;193-198.
21. Shweiki D., Neeman M., Itin A., Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc. Natl. Acad. Sci. USA. 92:1995;768-772.
22. The Kroc Collaborative Study Group, Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial, N. Engl. J. Med. 311 (1984) 365-372
23. Park S.H., Choi H.J., Lee J.H., Woo C.H., Kim J.H., Han H.J. High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-β1. Kidney Int. 59:2001;1695-1705.
24. Yamakawa K., Hosoi M., Koyama H., Tanaka S., Fukumoto S., Morii H., Nishizawa Y. Peroxisome proliferator-activated receptor-χ agonists increase vascular endothelial growth factor expression in human smooth muscle cells. Biochem. Biophys. Res. Commun. 271:2000;571-574.
25. Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motohashi M., Tanayama S. Disposition of AD-4833 (HCl), a new antidiabetic agent, in animals. Jpn. Pharmacol. Ther. 24:1996;2597-2617.
26. Williams B., Gallacher B., Patel H., Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes. 46:1997;1497-1503.
27. Isshiki K., Haneda M., Koya D., Maeda S., Sugimoto T., Kikkawa R. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes. 49:2000;1022-1032.
28. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor χ (PPARχ). J. Biol. Chem. 270:1995;12953-12956.
29. 2 metabolite binds peroxisome proliferator-activated receptor-χ and promotes adipocyte differentiation. Cell. 83:1995;813-819.
30. Sasaguri T., Masuda J., Shimokado K., Yokota T., Kosaka C., Fujishima M., Ogata J. Prostaglandins A and J arrest the cell cycle of cultured vascular smooth muscle cells without suppression of c-myc expression. Exp. Cell Res. 200:1992;351-357.